^
The fully automated IdyllaTM ctKRAS Mutation Test is minimally invasive, fast and easy to perform and can be used as complement to tissue testing to determine the RAS mutation status at diagnosis. IdyllaTM ctKRAS covers 21 KRAS mutations in exons 2,3 and 4 and showed an high concordance to NGS of 96% using plasma samples from 198 mCRC patients enrolled in the prospective multicenter RASANC study.
Cancer:
Colorectal Cancer
Gene:
KRAS (KRAS proto-oncogene GTPase)
Method:
PCR
Approvals
Date
Cancer
Gene
Drug
By
11/27/17
CE
Confirmatory trial(s)